Hologic [HOLX] vs West Pharmaceutical [WST] Detailed Stock Comparison
Hologic
NASDAQ
Loading...
West Pharmaceutical
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Hologic wins in 11 metrics, West Pharmaceutical wins in 8 metrics, with 0 ties. Hologic appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Hologic | West Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 28.24 | 36.05 | Hologic |
| Price-to-Book Ratio | 3.12 | 5.92 | Hologic |
| Debt-to-Equity Ratio | 52.09 | 10.52 | West Pharmaceutical |
| PEG Ratio | 14.42 | 32.07 | Hologic |
| EV/EBITDA | 12.64 | 21.65 | Hologic |
| Profit Margin (TTM) | 13.79% | 16.48% | West Pharmaceutical |
| Operating Margin (TTM) | 25.48% | 20.87% | Hologic |
| EBITDA Margin (TTM) | 25.48% | 20.87% | Hologic |
| Return on Equity | 11.38% | 17.72% | West Pharmaceutical |
| Return on Assets (TTM) | 6.69% | 10.53% | West Pharmaceutical |
| Free Cash Flow (TTM) | $1.15B | $276.40M | Hologic |
| Dividend Yield | N/A | 0.38% | N/A |
| 1-Year Return | -18.63% | -16.28% | West Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 3.75 | 5.86 | Hologic |
| Enterprise Value | $15.78B | $17.10B | West Pharmaceutical |
| EV/Revenue Ratio | 3.91 | 5.78 | Hologic |
| Gross Profit Margin (TTM) | 56.32% | 35.73% | Hologic |
| Revenue per Share (TTM) | $18 | $41 | West Pharmaceutical |
| Earnings per Share (Diluted) | $2.41 | $6.69 | West Pharmaceutical |
| Beta (Stock Volatility) | 0.49 | 1.05 | Hologic |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Hologic vs West Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hologic | 0.19% | 1.34% | 4.87% | 21.15% | 4.32% | -5.13% |
| West Pharmaceutical | 0.18% | 0.72% | 9.30% | 12.22% | -25.65% | -26.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hologic | -18.63% | -6.75% | 1.87% | 60.33% | 361.11% | 493.89% |
| West Pharmaceutical | -16.28% | -29.33% | -11.56% | 305.76% | 1,336.11% | 1,710.52% |
Performance & Financial Health Analysis: Hologic vs West Pharmaceutical
| Metric | HOLX | WST |
|---|---|---|
| Market Information | ||
| Market Cap | $15.14B | $17.34B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,889,880 | 723,326 |
| 90 Day Avg. Volume | 1,864,063 | 809,189 |
| Last Close | $68.06 | $240.98 |
| 52 Week Range | $51.90 - $84.67 | $187.43 - $352.33 |
| % from 52W High | -19.62% | -31.60% |
| All-Time High | $87.88 (May 01, 2023) | $475.35 (Sep 06, 2021) |
| % from All-Time High | -22.55% | -49.30% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.09% |
| Quarterly Earnings Growth | 0.00% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.16% |
| Operating Margin (TTM) | 0.25% | 0.21% |
| Return on Equity (TTM) | 0.11% | 0.18% |
| Debt to Equity (MRQ) | 52.09 | 10.52 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.79 | $40.74 |
| Cash per Share (MRQ) | $8.47 | $7.09 |
| Operating Cash Flow (TTM) | $1.07B | $676.70M |
| Levered Free Cash Flow (TTM) | $760.11M | $207.85M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.38% |
| Last 12-Month Dividend | N/A | $0.83 |
Valuation & Enterprise Metrics Analysis: Hologic vs West Pharmaceutical
| Metric | HOLX | WST |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 28.24 | 36.05 |
| Forward P/E | 14.42 | 32.07 |
| PEG Ratio | 14.42 | 32.07 |
| Price to Sales (TTM) | 3.75 | 5.86 |
| Price to Book (MRQ) | 3.12 | 5.92 |
| Market Capitalization | ||
| Market Capitalization | $15.14B | $17.34B |
| Enterprise Value | $15.78B | $17.10B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.91 | 5.78 |
| Enterprise to EBITDA | 12.64 | 21.65 |
| Risk & Other Metrics | ||
| Beta | 0.49 | 1.05 |
| Book Value per Share (MRQ) | $21.79 | $40.74 |
Financial Statements Comparison: Hologic vs West Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HOLX | WST |
|---|---|---|
| Revenue/Sales | $1.01B | $766.50M |
| Cost of Goods Sold | $628.00M | $492.60M |
| Gross Profit | $377.30M | $273.90M |
| Research & Development | $61.50M | $19.10M |
| Operating Income (EBIT) | $37.90M | $158.90M |
| EBITDA | $121.70M | $203.40M |
| Pre-Tax Income | $-28.50M | $157.00M |
| Income Tax | $-11.10M | $30.20M |
| Net Income (Profit) | $-17.40M | $131.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HOLX | WST |
|---|---|---|
| Cash & Equivalents | $1.43B | $509.70M |
| Total Current Assets | $3.21B | $1.68B |
| Total Current Liabilities | $989.70M | $604.60M |
| Long-Term Debt | $2.47B | $282.40M |
| Total Shareholders Equity | $4.62B | $2.93B |
| Retained Earnings | $3.03B | $4.14B |
| Property, Plant & Equipment | $939.80M | $3.28B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HOLX | WST |
|---|---|---|
| Operating Cash Flow | $28.40M | $177.40M |
| Capital Expenditures | $-24.70M | N/A |
| Free Cash Flow | $129.20M | $101.90M |
| Debt Repayment | $-10.20M | $-300,000 |
| Common Stock Repurchase | $-200.00M | $-500,000 |
Short Interest & Institutional Ownership Analysis
| Metric | HOLX | WST |
|---|---|---|
| Shares Short | 5.15M | 1.83M |
| Short Ratio | 2.16 | 2.92 |
| Short % of Float | 0.03% | 0.03% |
| Average Daily Volume (10 Day) | 1,889,880 | 723,326 |
| Average Daily Volume (90 Day) | 1,864,063 | 809,189 |
| Shares Outstanding | 231.73M | 72.30M |
| Float Shares | 220.31M | 71.39M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.03% | 0.99% |
Dividend Analysis & Yield Comparison: Hologic vs West Pharmaceutical
| Metric | HOLX | WST |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.83 |
| Last 12-Month Dividend Yield | N/A | 0.38% |
| 3-Year Avg Annual Dividend | N/A | $0.79 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $2.37 |
| Ex-Dividend Date | N/A | Apr 30, 2025 |